Syncona Ltd, an active investor in cell and gene therapy, has joined the Novartis Venture Fund to provide CHF 35 million (€31 million) in Series A funding to Anaveon AG, a Swiss start-up which is developing biologics for cancer.
Founded in December 2017, Anaveon has a preclinical product targeting the interleukin 2 (IL-2) receptor. The biologic is an agonist which is expected to enhance a patient’s immune system to respond to tumours and work better than other IL-2 products.